TP53 and posterior cortical atrophy: Given the considerable number of PCa patients with MMS22L deletion detected by next-generation sequencing- or DNA in situ hybridization-based assays, this genomic alteration may be a valuable biomarker for PARP inhibition despite the fact that the response is TP53-dependent.